Semaglutide vs Empagliflozin: Which Drug Has Better Real-World Adherence?

What the researchers found

Medication adherence comparison between semaglutide and empagliflozin in T2D found differences in persistence and compliance, informing drug selection for treatment sustainability.

Why it matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The numbers in context

Retrospective study comparing adherence and persistence between semaglutide and empagliflozin using pharmacy dispensing data.

How the study worked

Study methodology detailed in the full publication.

Who was studied

Adults with type 2 diabetes at a military hospital in Tabuk, Saudi Arabia

What this study cannot tell us

Study limitations in the full publication.

How to read the evidence

Evidence level based on study design in publication.

When this study was published

Published in 2025.

The bigger picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

Questions still open

• What are the long-term implications?
• How do results compare to other evidence?
• What further research is needed?

Common questions

Read the original research

Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.

Patient preference and adherence, 19, 4179-4190

Citation

Ali, Mostafa A S; Amirthalingam, Palanisamy; Alshareef, Hanan; Alqifari, Saleh F; Elsaid Hamdan, Ahmed Mohsen; Alatawi, Olayan; Hakami, Faris Ahmed M; Albalawi, Nader Salem; Aljabri, Ahmed. (2025). Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.. Patient preference and adherence, 19, 4179-4190. https://doi.org/10.2147/PPA.S569096